G.R. No. 166924 - GlaxoSmithKline Philippines, Inc. vs. Malik

Glaxo, together with Pfizer and Roche, filed separate letter-complaints alleging that the respondents, Khalid Mehmood Malik and Muhammad Ateeque, were engaged in the illegal sale and distribution of unregistered imported pharmaceutical drugs.
The alleged offenses took place at business establishments in ParaAaque City, namely, World Traders, Inc. and the Sahar International Trading Center (SITI).

Acting on these complaints, the National Bureau of Investigation (NBI) Intellectual Property Rights Division, led by Agent Rodolfo Ignacio and assisted by investigators from the private firm IP Manila Associates (hired by Glaxo, Pfizer, and Roche), conducted surveillance at the respondents’ location.
During the operation, respondent Muhammad Ateeque purportedly displayed samples of medicines that lacked the requisite registration numbers issued by the Bureau of Food and Drugs (BFAD).
A subsequent entrapment operation on June 9, 2002, at SITI led to respondent Malik allegedly being caught receiving marked money from an undercover team member in exchange for parallel imported drugs, after which Malik was arrested and found to have fluorescent powder on him.

Prompted by the evidence, petitioner Glaxo concluded that the pharmaceutical samples did not meet its stringent standards; an inquest investigation was then conducted by Inquest Prosecutor Albert R. Fonacier of the Department of Justice (DOJ) on June 10, 2002.
Criminal Cases No. 02-0699 to No. 0701 were filed before the Regional Trial Court of ParaAaque City, Branch 258, charging Malik with violations of Republic Act (RA) No. 3720 (Food, Drugs and Cosmetic Act) and RA No. 8203 (Special Law on Counterfeit Drugs).
Respondent Ateeque, being at large at the time, had a preliminary investigation commenced against him by State Prosecutor Isagani Rabe.

Following a motion by respondent Malik, the DOJ consolidated the investigations against both respondents into I.S. No. 2002-515.
On January 14, 2003, Senior State Prosecutor Leah C. Tanodra-Armamento issued a resolution dismissing the charges against both respondents due to the insufficiency of the evidence and inconsistencies in the complaint affidavits.
Glaxo’s subsequent motion for reconsideration was denied on February 18, 2003.

Dissatisfied with the dismissal, Glaxo filed a petition for review with the Secretary of Justice, which was dismissed on June 17, 2003, on the basis that no error had been committed in the prosecutor’s resolution.
Similar petitions by Pfizer and Roche were dismissed on June 25, 2003.
Glaxo then elevated the matter by filing a petition for certiorari with the Court of Appeals (CA) in CA-G.R. SP No. 78646, alleging grave abuse of discretion by the Secretary of Justice.
The CA, in its Decision dated October 28, 2004, and affirming resolution dated January 24, 2005, denied Glaxo’s petition, finding no grave abuse of discretion.
Ultimately, Glaxo elevated the case to the Supreme Court via a petition for review, challenging whether courts may substitute their judgment for that of the prosecutor on the issue of probable cause.

Whether the courts may review and override the prosecutorial findings on probable cause during preliminary or reinvestigations.

The issue centers on whether judicial authorities can substitute their judgment for that of the prosecuting officer in determining the sufficiency of evidence to establish guilt.
It questions the extent of judicial intervention in matters that are traditionally within the prosecutorial discretion.

Whether the dismissal of the criminal charges and the subsequent resolutions were tainted by grave abuse of discretion.

The issue involves determining if the decisions of the Senior State Prosecutor and the Secretary of Justice were arbitrary, capricious, or manifestly against the evidence presented.
It considers if such decisions merit judicial scrutiny and intervention.